Biotech Values

[dewophile]

idix
"Based on the CC guidance about cash usage in 2009, I don’t think shorting based on the expectation of a financing deal explains the recent share-price dynamics"

they have a year's worth of cash. what sources of non-dilutive funding does the company have? 3 possibilities that come to mind are:
1. licensing of 184 - but could this be a 2009 event? how long does NVS have to exercise licensing after proof of concept? and does the 3 day monotherapy constitute proof of concept or will they have to wait for the 2 week combo with SOC?
2. milestones from GSK - idix evaded all questions re timing of milestones which leads me to think not much near-term (maybe modest clinical milestone at start ph 2 this year?)
3. selling tyzeka royalty stream - but at 900k/quarter with little growth expected not quite sure what they could get for it

am i missing something? what gives you such confidence a financing (even at depressed stock price) won't happen this year